Monica Crugnola

Parma, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 09, 2026

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Journal: Cancers

Published: April 08, 2026

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Journal: Leukemia research

Published: March 06, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

Journal: European journal of haematology

Published: February 24, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Journal: Cancer

Published: February 19, 2026

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Journal: Cancer

Published: December 16, 2025

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology

Published: November 13, 2025

Long-term health-related quality of life and lifestyle behavior of patients with acute myeloid leukemia.

Long-term health-related quality of life and lifestyle behavior of patients with acute myeloid leukemia.

Journal: The oncologist

Published: September 23, 2025

Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.

Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.

Journal: Cancer

Published: May 12, 2025

Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.

Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.

Journal: Cancer

Published: May 06, 2025

Showing 1-12 of 84

Last Updated: 09/26/2026